New publications in health economics and genomics 3rd January 2023

Two publications since 14th December:

  • A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice | link
  • Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Weekly updates will return from this week onwards.

New publications in health economics and genomics 13th December 2022

One publication from the past week:

  • The PrU: development and validation of a measure to assess personal utility of genomic results | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

There will be no posts for the next two weeks due to the Christmas break. The next post will be on 3rd January.

New publications in health economics and genomics 29th November 2022

Three publications from the past week:

  • Cost-effectiveness of a gene sequencing test for Alzheimer’s disease in Ontario | link
  • Key drivers of family-level utility of pediatric genomic sequencing: a qualitative analysis to support preference research | link
  • A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

New publications in health economics and genomics 15th November 2022

Two publications from the past week:

  • Whole-Exome Sequencing’s Cost-Effectiveness in Children with Increasing Neurological Problems | link
  • Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

New publications in health economics and genomics 2nd November 2022

Two publications from the past week:

  • Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness? | link
  • A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

New publications in health economics and genomics 18th October 2022

Three publications from the past week:

  • Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands | link
  • The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA | link
  • Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

New publications in health economics and genomics 11th October 2022

Three publications from the past week:

  • A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials | link
  • Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation | link
  • Applying the Clinician-reported Genetic testing Utility InDEx (C-GUIDE) to genome sequencing: further evidence of validity | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

New publications in health economics and genomics 5th October 2022

Nine publications from the past two weeks:

  • Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions | link
  • Reduced resource utilization with early use of next-generation sequencing in rare genetic diseases in an Asian cohort | link
  • Resource allocation in genetic and genomic medicine | link (the rest of this Special Issue is available here)
  • Correspondence on “Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions” by Lavelle et al | link
  • Response to Grosse and Gudgeon | link
  • Economic Aspects in Precision Medicine and Pharmacogenomics | link
  • Economic evaluation of using polygenic risk score to guide risk screening and interventions for the prevention of type 2 diabetes in individuals with high overall baseline risk | link
  • Epistemic justice, African values and feedback of findings in African genomics research | link
  • Reduced resource utilization with early use of next-generation sequencing in rare genetic diseases in an Asian cohort | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Journal Special Issue published on Resource Allocation in Genetic and Genomic Medicine

I’m pleased to announce the publication of a Special Issue of the Journal of Community Genetics, which I edited with Ilias Goranitis and Ingrid Slade.

https://link.springer.com/journal/12687/volumes-and-issues/13-5

Titled: “Resource Allocation in Genetic and Genomic Medicine”, this Special Issue features 6 papers and an editorial, and grew out of a conference we organised at HERC in 2018 with the Centre for Personalised Medicine and the Ethox Centre, both in Oxford, titled “Resource Allocation in Personalised Medicine: Evaluation, Translation and Ethics”.

You can view presentations from this conference here: https://cpm.well.ox.ac.uk/term/resource-allocation-ethics-and-market

Although the Special Issue has now been published, a virtual collection remains open to receive further articles on this topic. You can access this virtual collection here: https://link.springer.com/collections/hdbhhddibh

Vacancy for researcher in health economics and genomics

HERC are currently advertising vacancies for two researchers in health economics (https://www.herc.ox.ac.uk/about/work-with-us).

These researchers will work across multiple projects, one of which is a project with me, titled: “Psychometric assessment of EQ-5D-5L, EQ-HWB and EQ-5D-Y-5L in rare genetic diseases”.

Genomic testing is starting to be translated into clinical practice for people with rare genetic diseases. In England, the National Health Service has recently launched a new Genomic Medicine Service. However, data on the outcomes of genomic testing is sparse, and there is uncertainty regarding the appropriate outcome measures to use. Data on the use of both established and new instruments, such as the EQ-5D-5L, EQ-HWB and EQ-5D-Y-5L, would inform more robust health technology assessment decisions in this context. This work will involve assessing the psychometric properties of the EQ-5D-5L, EQ-HWB, and EQ-5D-Y-5L instruments in adult patients and parents of children with lived experience of rare genetic diseases using mixed methods. Recruitment for this study will take place in both England and Australia, in conjunction with collaborators at the University of Melbourne, lead by Ilias Goranitis.

The closing date for applications is 12.00 noon on Thursday 03 November 2022.

If you have any questions, or would like to discuss the vacancy, please email me at james.buchanan@dph.ox.ac.uk